Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson's disease. Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.
Li, Fan; Hou, Xingpu; Li, Lin; Lu, Tao; Du, Yumin. Synthesis of antiparkinsonian agent istradefylline. Zhongguo Yiyao Gongye Zazhi. Volume 41. Issue 4. Pages 241-243. Journal. (2010).
LaBeaume, Paul; Dong, Ma; Sitkovsky, Michail; Jones, Elizabeth V.; Thomas, Rhiannon; Sadler, Sara; Kallmerten, Amy E.; Jones, Graham B. An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives. Organic & Biomolecular Chemistry. Volume 8. Issue 18. Pages 4155-4157. Journal. (2010).
Jorg, Manuela; Shonberg, Jeremy; Mak, Frankie S.; Miller, Neil D.; Yuriev, Elizabeth; Scammells, Peter J.; Capuano, Ben. Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space. Bioorganic & Medicinal Chemistry Letters. Volume 23. Issue 11. Pages 3427-3433. Journal; Online Computer File. (2013).
No Data
Wang, Zhenyu; Liu, Yanhua. Process for preparation of istradefylline. Assignee Hangzhou SIMBOS Pharmaceutical Co., Ltd., Peop. Rep. China. CN 106632332. (2017).
